Correlation Between Eupraxia Pharmaceuticals and Lumos Pharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Eupraxia Pharmaceuticals and Lumos Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Eupraxia Pharmaceuticals and Lumos Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Eupraxia Pharmaceuticals and Lumos Pharma, you can compare the effects of market volatilities on Eupraxia Pharmaceuticals and Lumos Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Eupraxia Pharmaceuticals with a short position of Lumos Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Eupraxia Pharmaceuticals and Lumos Pharma.

Diversification Opportunities for Eupraxia Pharmaceuticals and Lumos Pharma

-0.32
  Correlation Coefficient

Very good diversification

The 3 months correlation between Eupraxia and Lumos is -0.32. Overlapping area represents the amount of risk that can be diversified away by holding Eupraxia Pharmaceuticals and Lumos Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Lumos Pharma and Eupraxia Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Eupraxia Pharmaceuticals are associated (or correlated) with Lumos Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Lumos Pharma has no effect on the direction of Eupraxia Pharmaceuticals i.e., Eupraxia Pharmaceuticals and Lumos Pharma go up and down completely randomly.

Pair Corralation between Eupraxia Pharmaceuticals and Lumos Pharma

If you would invest  279.00  in Eupraxia Pharmaceuticals on August 28, 2024 and sell it today you would earn a total of  0.00  from holding Eupraxia Pharmaceuticals or generate 0.0% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy4.76%
ValuesDaily Returns

Eupraxia Pharmaceuticals  vs.  Lumos Pharma

 Performance 
       Timeline  
Eupraxia Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Eupraxia Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, Eupraxia Pharmaceuticals is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders.
Lumos Pharma 

Risk-Adjusted Performance

3 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Lumos Pharma are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of very weak primary indicators, Lumos Pharma may actually be approaching a critical reversion point that can send shares even higher in December 2024.

Eupraxia Pharmaceuticals and Lumos Pharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Eupraxia Pharmaceuticals and Lumos Pharma

The main advantage of trading using opposite Eupraxia Pharmaceuticals and Lumos Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Eupraxia Pharmaceuticals position performs unexpectedly, Lumos Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lumos Pharma will offset losses from the drop in Lumos Pharma's long position.
The idea behind Eupraxia Pharmaceuticals and Lumos Pharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.

Other Complementary Tools

Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope